

Date: 06th February, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APL LTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of extract of Unaudited Financial Results for the quarter and nine months ended 31st December, 2025, published in Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 06th February, 2026.


We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited


Manisha Saraf
Company Secretary



Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN: L24230GJ2010PLC061123

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results
for the quarter ended 31st December, 2025****(₹ in Crores except per share data)**

Particulars	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations	1,876.31	1,692.74	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	203.73	177.78	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	161.50	177.78	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	132.97	138.42	583.42
Total Comprehensive Income for the period	139.90	139.71	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	6.76	7.01	29.68

Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Income from Operations	1,642.24	1,406.09	6,032.63
Profit Before Tax	181.02	103.81	595.72
Profit After Tax	114.47	85.81	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

**For Alembic Pharmaceuticals Limited**

Sd/-

Pranav Amin**Managing Director****Place : Vadodara****Date : 5th February, 2026**

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results
for the quarter ended 31st December, 2025**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations	1,876.31	1,692.74	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	203.73	177.78	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	161.50	177.78	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	132.97	138.42	583.42
Total Comprehensive Income for the period	139.90	139.71	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	6.76	7.01	29.68

Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Income from Operations	1,642.24	1,406.09	6,032.63
Profit Before Tax	181.02	103.81	595.72
Profit After Tax	114.47	85.81	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited
Sd/-

Place : Vadodara

Date : 5th February, 2026Pranav Amin
Managing Director

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results
for the quarter ended 31st December, 2025**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations	1,876.31	1,692.74	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	203.73	177.78	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	161.50	177.78	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	132.97	138.42	583.42
Total Comprehensive Income for the period	139.90	139.71	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	6.76	7.01	29.68

Notes:

1. Standalone details	Quarter Ended		Year Ended
	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
Income from Operations	1,642.24	1,406.09	6,032.63
Profit Before Tax	181.02	103.81	595.72
Profit After Tax	114.47	85.81	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Place : Vadodara

Date : 5th February, 2026Pranav Amin
Managing Director